Últimos Artículos de Terapeuthic Advances in Endocrinolgy and Metabolism
- Non-pharmacological management options for MAFLD: a practical guide
- The role of supporting and disruptive mechanisms of FT3 homeostasis in regulating the hypothalamic–pituitary–thyroid axis
- Tackling diabetic foot: limb salvage during the COVID-19 pandemic
- Immune checkpoint inhibitors: friend or foe for osteoporosis
- MAFLD: a multisystem disease
- Screening for MAFLD: who, when and how?
- Influence of the occurrence and duration of partial remission on short-term metabolic control in type 1 diabetes: the DIABHONEY pediatric study
- Differences in adherence to using removable cast walker treatment during daytime and nighttime weight-bearing activities in people with diabetes-related foot ulcers
- Emerging pharmacological treatment options for MAFLD
- Effect of sodium-glucose cotransporter-2 inhibitors on patients with essential hypertension and pre-hypertension: a meta-analysis
- A case of pheochromocytoma associated with liver abscess and intestinal pseudo-obstruction
- Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease
- Non-invasive assessment of metabolic dysfunction–associated fatty liver disease
- Potential immunological effects of gender-affirming hormone therapy in transgender people – an unexplored area of research
- MAFLD: what 2 years of the redefinition of fatty liver disease has taught us
- Characterizing palliative care needs in people with or at risk of developing diabetic foot ulcers
- Hyponatraemia in patients on immune checkpoint inhibitors
- Update on genetics and epigenetics in metabolic associated fatty liver disease
- Menopause, androgens, and cardiovascular ageing: a narrative review
- Impact of metformin on the clinical and metabolic parameters of women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials